glp 1 vision changes Frontiers Rare GLP-1 Vision Loss Risks

Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans

mBio 8 , e0159517 (2017)

The mechanism of action is fundamentally different, targeting incretin receptors in the pancreas, brain, and gut rather than the kidneys

You should discuss cancer concerns with your GP or specialist before starting a GLP-1 medicine if you have: Personal history of any cancer, particularly thyroid or pancreatic malignancies Family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 Previous episodes of pancreatitis Unexplained symptoms such as persistent abdominal pain, neck lumps, or difficulty swallowing Anxiety about cancer risk that may affect medicine adherence During treatment with a GLP-1 medicine, contact your healthcare provider promptly if you develop: A lump or swelling in the neck Persistent hoarseness or voice changes Difficulty swallowing or breathing Severe, persistent abdominal pain, especially if radiating to the back (seek urgent medical help via NHS 111 or A&E if severe) Unexpected or disproportionate weight loss relative to your dose and treatment plan, especially with other concerning symptoms Any other worrying symptoms It is important to maintain perspective: the proven cardiovascular benefits of GLP-1 medicines in reducing heart attack, stroke, and cardiovascular death substantially outweigh theoretical cancer concerns for most patients

A pilot 8-week double-blind trial delved into the feasibility and safety of FMT in adults with moderate to severe MDD (Green et al., 2023)

This condition is more dramatic throughout childhood, where both skeletal maturation and organ growth are retarded[19, 34, 202] probably due to a lower impact of GH on gestational growth as compared to IGF-I[3140]